Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) generates frequent news flow as a clinical-stage biotechnology company developing neflamapimod for dementia with Lewy bodies (DLB) and other age-related brain disorders. The company’s updates often center on clinical data releases, regulatory interactions, and corporate developments tied to its lead program.
Investors following CRVO news can expect detailed announcements on results from the Phase 2b RewinD-LB trial in DLB, including subgroup analyses, biomarker findings, and longer-term extension data. CervoMed has reported that neflamapimod treatment in DLB was associated with effects on the Clinical Dementia Rating – Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), and plasma biomarkers such as glial fibrillary acidic protein (GFAP), Aβ42/40 ratio, and neurofilament light. These news items provide insight into how the company interprets clinical and biomarker outcomes in its target population, particularly patients with a low likelihood of Alzheimer’s disease co-pathology.
CervoMed’s news flow also includes regulatory milestones, such as written feedback from the U.S. Food and Drug Administration aligning on key aspects of the planned Phase 3 trial design in DLB. Articles may describe planned trial parameters, enrichment strategies using plasma ptau181, and the role of CDR-SB as the primary endpoint. Additional coverage highlights participation in scientific conferences, presentations at dementia and neurology meetings, and dissemination of new analyses of trial data.
Beyond clinical and regulatory updates, CRVO news features quarterly financial results, grant funding details, and changes to the company’s leadership and board composition. Announcements of executive appointments, board expansions, and investor conference participation help contextualize CervoMed’s preparation for late-stage development and potential commercialization of neflamapimod. This news page aggregates these items so readers can track how scientific results, regulatory feedback, and corporate actions evolve over time.
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Sidoti Virtual Micro Cap Conference on November 14 at 2:30 PM ET and the Stifel 2024 Healthcare Conference on November 19 at 3:00 PM ET. Both presentations will be available via webcast and accessible through CervoMed's website investor section.
CervoMed presented key findings at the CTAD Conference regarding neflamapimod's potential in treating dementia with Lewy bodies (DLB). The presentations highlighted significant reduction in plasma GFAP levels (p=0.015 vs placebo) in Phase 2a trials, indicating reduced neurodegenerative disease activity. The ongoing RewinD-LB Phase 2b study successfully enrolled DLB patients without tau pathology, optimizing the potential treatment effect. The study's sample size of 80 patients per arm provides nearly 100% statistical power for meeting its primary endpoint. Topline results are expected in December.
CervoMed (NASDAQ: CRVO) announced it will present detailed safety and efficacy results from its RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the International Lewy Body Dementia Conference in January 2025. The company expects to release topline data from the study in December 2024. The presentation will take place during the Therapeutics in DLB session on January 31, 2025.
CEO John Alam expressed confidence in the trial design's ability to detect statistically significant and clinically meaningful differences between neflamapimod and placebo, noting there are currently no approved therapies for DLB.
CervoMed Inc. (NASDAQ: CRVO) has announced the Last Patient Last Visit in its Phase 2b RewinD-LB clinical trial evaluating neflamapimod for early-stage dementia with Lewy bodies (DLB). The company is on track to report topline efficacy and safety data in December 2024. Key highlights include:
- 96% of enrolled patients completed the 16-week double-blind placebo-controlled portion
- 98% of those patients continued into the open label extension
- The Data Safety Monitoring Board concluded the study may proceed without modification
- CervoMed will present late-breaking oral presentations at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference
The company believes neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients, addressing a significant unmet need in this population.
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for age-related neurologic disorders, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference in New York on October 9, 2024. Dr. John Alam, CEO of CervoMed, will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications' at 8:00am ET.
The conference provides CervoMed with a platform to engage with investors through one-on-one meetings, potentially increasing visibility for the company's innovative approach to addressing age-related neurologic disorders. This event offers an opportunity for CervoMed to showcase its progress and strategy in pursuing significant market opportunities within the healthcare sector.
CervoMed Inc. (NASDAQ: CRVO) announced two late-breaking oral presentations at the upcoming Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain. The presentations will focus on the potential of neflamapimod as a treatment for dementia with Lewy bodies (DLB). The first presentation will discuss plasma biomarker data from the AscenD-LB Phase 2a study, indicating neflamapimod's effect on the underlying disease process in DLB. The second presentation will cover baseline data from the RewinD-LB Phase 2b study, demonstrating the disease burden at study entry. CervoMed's CEO, John Alam, expressed confidence in a positive outcome for the RewinD-LB trial, with topline data expected in December 2024.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: A fireside chat on Friday, September 6, 2024, at 1:50 PM ET.
2. H.C. Wainwright 26th Annual Global Investment Conference: A corporate presentation on Wednesday, September 11, 2024, at 8:30 AM ET.
Webcasts of both presentations will be available on the CervoMed website's Investor section. These conferences provide an opportunity for CervoMed to showcase its progress and engage with potential investors.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, was featured in Fortune magazine for its work on neflamapimod, a potential treatment for dementia with Lewy bodies (DLB). The article, "A New Hope for Dementia Treatment," highlights CervoMed's Phase 2a AscenD-LB trial results, which suggest neflamapimod may slow cognitive and motor decline and partially restore functions in DLB patients.
CEO John Alam emphasized the critical need for DLB treatments, noting it affects over 1.4 million people in the U.S. The company anticipates sharing topline results from its Phase 2b RewinD-LB study in December 2024. Additionally, Dr. Alam recently discussed CervoMed's advancements on the Biotech 2050 podcast.
CervoMed Inc. (NASDAQ: CRVO) reported its Q2 2024 financial results and provided corporate updates. Key highlights include:
1. Completed enrollment in the RewinD-LB Phase 2b trial for neflamapimod in early-stage dementia with Lewy bodies (DLB), with topline data expected in December 2024.
2. Raised up to $149.4 million in a private placement, extending cash runway through 2025.
3. Added to Russell 2000® and Russell 3000® Indexes.
4. Q2 2024 financials: $50.9 million cash on hand, $5.6 million grant revenue for H1 2024, R&D expenses of $3.8 million, G&A expenses of $2.5 million, and a net loss of $2.3 million.
The company remains focused on developing treatments for age-related neurologic disorders, with neflamapimod showing potential in DLB and other neurological conditions.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 13, 2024, at 12:30 PM ET.
Investors can access the webcast of the fireside chat through a provided link or via the Investors section of CervoMed's website. Additionally, the company will be available for one-on-one investor meetings during the conference, offering an opportunity for more in-depth discussions about CervoMed's progress and future plans in the field of neurologic disorder treatments.